LDLR and atherosclerosis: While we previously showed that SH42 was very effective in attenuating experimental peritonitis16 and metabolic dysfunction-associated steatohepatitis,17 we did not observe an effect of SH42 treatment on atherosclerotic lesion area, severity or markers of plaque stability either in E3L.CETP mice, a model for lipid-driven atherosclerosis, or in LDLr-KO mice, a model of inflammation-driven atherosclerosis.